141 related articles for article (PubMed ID: 20380637)
1. Mechanisms of cytotoxicity of anticancer titanocenes.
Olszewski U; Hamilton G
Anticancer Agents Med Chem; 2010 May; 10(4):302-11. PubMed ID: 20380637
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activity and mode of action of titanocene C.
Olszewski U; Claffey J; Hogan M; Tacke M; Zeillinger R; Bednarski PJ; Hamilton G
Invest New Drugs; 2011 Aug; 29(4):607-14. PubMed ID: 20162321
[TBL] [Abstract][Full Text] [Related]
3. Anti-proliferative activity and mechanism of action of titanocene dichloride.
Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ
Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119
[TBL] [Abstract][Full Text] [Related]
4. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
[TBL] [Abstract][Full Text] [Related]
5. Antitumor titanium compounds.
Caruso F; Rossi M
Mini Rev Med Chem; 2004 Jan; 4(1):49-60. PubMed ID: 14754443
[TBL] [Abstract][Full Text] [Related]
6. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes.
Kelter G; Sweeney NJ; Strohfeldt K; Fiebig HH; Tacke M
Anticancer Drugs; 2005 Nov; 16(10):1091-8. PubMed ID: 16222151
[TBL] [Abstract][Full Text] [Related]
7. Alterations of phosphoproteins in NCI-H526 small cell lung cancer cells involved in cytotoxicity of cisplatin and titanocene Y.
Olszewski U; Deally A; Tacke M; Hamilton G
Neoplasia; 2012 Sep; 14(9):813-22. PubMed ID: 23019413
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity studies of Ti(IV) complexes: aqueous stability and cytotoxic properties in colon cancer HT-29 cells.
Hernández R; Lamboy J; Gao LM; Matta J; Román FR; Meléndez E
J Biol Inorg Chem; 2008 Jun; 13(5):685-92. PubMed ID: 18288505
[TBL] [Abstract][Full Text] [Related]
9. Differential cytotoxicity induced by the Titanium(IV)Salan complex Tc52 in G2-phase independent of DNA damage.
Pesch T; Schuhwerk H; Wyrsch P; Immel T; Dirks W; Bürkle A; Huhn T; Beneke S
BMC Cancer; 2016 Jul; 16():469. PubMed ID: 27412346
[TBL] [Abstract][Full Text] [Related]
10. Effects of titanocene dichloride derivatives on prostate cancer cells, specifically DNA damage-induced apoptosis.
Cuffe S; Dowling CM; Claffey J; Pampillón C; Hogan M; Fitzpatrick JM; Carty MP; Tacke M; Watson RW
Prostate; 2011 Feb; 71(2):111-24. PubMed ID: 20665530
[TBL] [Abstract][Full Text] [Related]
11. Antitumour bis(cyclopentadienyl) metal complexes: titanocene and molybdocene dichloride and derivatives.
Abeysinghe PM; Harding MM
Dalton Trans; 2007 Aug; (32):3474-82. PubMed ID: 17680034
[TBL] [Abstract][Full Text] [Related]
12. Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo.
Bannon JH; Fichtner I; O'Neill A; Pampillón C; Sweeney NJ; Strohfeldt K; Watson RW; Tacke M; Mc Gee MM
Br J Cancer; 2007 Nov; 97(9):1234-41. PubMed ID: 17923871
[TBL] [Abstract][Full Text] [Related]
13. Dimethylamino-functionalised and N-heteroaryl-substituted titanocene anticancer drugs: synthesis and cytotoxicity studies.
Hickey T; Claffey J; Fitzpatrick E; Hogan M; Pampillón C; Tacke M
Invest New Drugs; 2007 Oct; 25(5):425-33. PubMed ID: 17516024
[TBL] [Abstract][Full Text] [Related]
14. Study of the cytotoxicity and particle action in human cancer cells of titanocene-functionalized materials with potential application against tumors.
García-Peñas A; Gómez-Ruiz S; Pérez-Quintanilla D; Paschke R; Sierra I; Prashar S; del Hierro I; Kaluđerović GN
J Inorg Biochem; 2012 Jan; 106(1):100-10. PubMed ID: 22112846
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cytotoxic activity of titanocene difluorides and determination of their mechanism of action in ovarian cancer cells.
Koubkova L; Vyzula R; Karban J; Pinkas J; Ondrouskova E; Vojtesek B; Hrstka R
Invest New Drugs; 2015 Oct; 33(5):1123-32. PubMed ID: 26205069
[TBL] [Abstract][Full Text] [Related]
16. Antitumour metallocenes: structure-activity studies and interactions with biomolecules.
Harding MM; Mokdsi G
Curr Med Chem; 2000 Dec; 7(12):1289-303. PubMed ID: 11032972
[TBL] [Abstract][Full Text] [Related]
17. Titanium(IV) complexes: cytotoxicity and cellular uptake of titanium(IV) complexes on caco-2 cell line.
Hernández R; Méndez J; Lamboy J; Torres M; Román FR; Meléndez E
Toxicol In Vitro; 2010 Feb; 24(1):178-83. PubMed ID: 19772913
[TBL] [Abstract][Full Text] [Related]
18. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells.
O'Connor K; Gill C; Tacke M; Rehmann FJ; Strohfeldt K; Sweeney N; Fitzpatrick JM; Watson RW
Apoptosis; 2006 Jul; 11(7):1205-14. PubMed ID: 16699961
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization, cytotoxicity, and hydrolytic behavior of C2- and C1-symmetrical Ti(IV) complexes of tetradentate diamine bis(phenolato) ligands: a new class of antitumor agents.
Peri D; Meker S; Shavit M; Tshuva EY
Chemistry; 2009; 15(10):2403-15. PubMed ID: 19156656
[TBL] [Abstract][Full Text] [Related]
20. Pseudo-halide derivatives of titanocene: synthesis and cytotoxicity studies.
Claffey J; Deally A; Gleeson B; Hogan M; Méndez LM; Müller-Bunz H; Patil S; Wallis D; Tacke M
Metallomics; 2009 Nov; 1(6):511-7. PubMed ID: 21305159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
